Advertisement

Cancer Immunology, Immunotherapy

, Volume 33, Issue 6, pp 389–394 | Cite as

Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour

  • Riks A. Maas
  • D. Henk
  • J. Van Weering
  • Hub F. J. Dullens
  • Willem Den Otter
Original articles

Summary

This study shows that local tumour treatment with low-dose recombinant interleukin-2 (IL-2) can mediate rejection of a large distant solid tumour. When SL2 lymphoma cells were injected intraperitoneally (i.p.) in syngeneic DBA/2 mice on day 0, 70% of these mice were cured by daily i. p. injections with 20 000 units IL-2 on days 10–14. After injecting mice with SL2 both i.p. and subcutaneously (s. c.) on the flank, 50% of the mice treated i.p. with low-dose IL-2 rejected both the i.p. tumour and the large distant s.c. tumour. In contrast, i.p. IL-2 treatment on days 10–14 cured fewer than 10% of the mice bearing only a s. c. SL2 tumour. The described IL-2 immunotherapy also caused systemic tumour rejection in mice bearing both ascitic and solid P815 mastocytoma. Thus it was shown that low-dose IL-2 can induce systemic tumour rejection, when injected at a site of tumour growth. Interleukin-2-induced rejection of s. c. SL2 tumour was highly specific, as mice that were rejecting i.p. and solid s. c. SL2 lymphoma did not reject solid P815 mastocytoma, which was injected s.c. simultaneously on the other flank. Furthermore, solid s.c. tumours consisting of mixtures of SL2 and P815 were not rejected in mice that rejected i.p. SL2 or P815. We conclude that intratumoral injections of low-dose IL-2 can enhance an ongoing weak immune reaction against the tumour resulting in systemic tumour rejection.

Key words

Immunotherapy Interleukin-2 SL2 lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, Forni G (1990) Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 145: 3136Google Scholar
  2. 2.
    Bubenik J (1989) Local immunotherapy of cancer with interleukin-2. Immunol Lett 21: 267Google Scholar
  3. 3.
    Bubenik J, Indrova M (1987) The anti-tumor efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo. Cancer Immunol Immunother 24: 269Google Scholar
  4. 4.
    Dullens HFJ, Hilgers J, Spit BJ, De Heer E, De Weger RA, Van Basten CDH, Den Otter W (1982) Staging, growth properties and metastatic behaviour of a transplantable murine T-cell lymphoma. Int J Tissue React 4: 15Google Scholar
  5. 5.
    Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80: 177Google Scholar
  6. 6.
    Ferrara P, Pecceu F, Marchese E, Vita N, Roskam W, Lupker J (1987) Characterization of recombinant glycosylated human interleukin 2 produced by a recombinant plasmid transformed CHO cell line. FEBS Lett 226: 47Google Scholar
  7. 7.
    Forni G, Giovarelli M, Santoni A, Modesti A, Forni M (1987) Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 138: 4033Google Scholar
  8. 8.
    Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49: 7037Google Scholar
  9. 9.
    Mulé JJ, Shu S, Schwartz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science 225: 1487Google Scholar
  10. 10.
    Mulé JJ, Yang J, Shu S, Rosenberg SA (1986) The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastasis and cytolytic activity of lymphokine-activated killer cells. J Immunol 136: 3899Google Scholar
  11. 11.
    Nishimura T, Ohta S, Sato N, Togashi Y, Goto M, Hashimoto Y (1987) Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int J Cancer 40: 255Google Scholar
  12. 12.
    Palladino Jr MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, Liggit D, Patton JS (1987) Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 138: 4023Google Scholar
  13. 13.
    Papa MZ, Mulé JJ, Rosenberg SA (1986) Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in-vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res 46: 4972Google Scholar
  14. 14.
    Peace DJ, Cheever MA (1989) Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 169: 161Google Scholar
  15. 15.
    Proietti E, Belardelli F, Carpinelli G, Di Vito M, Woodrow D, Moss J, Sestili P, Fiers W, Gresser I, Podo F (1988) Tumor necrosis factor α induces early morphologic and metabolic alterations in Friend leukemia cell tumors and fibrosarcomas in mice. Int J Cancer 42: 582Google Scholar
  16. 16.
    Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med, 161: 1169Google Scholar
  17. 17.
    Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474Google Scholar
  18. 18.
    Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, Den Otter W, Steerenberg PA, De Jong WH, Ruitenberg EJ (1989) Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. Cancer Immunol Immunother 30: 165Google Scholar
  19. 19.
    Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R (1987) Systematic preclinical study of the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47: 5725Google Scholar
  20. 20.
    Tanida S, Uchida H, Taniguchi K, Nomoto K (1989) Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice. Cancer Res 49: 284Google Scholar
  21. 21.
    Thompson JA, Peace DJ, Klarnet JP, Kern PE, Greenberg PD, Cheever MA (1986) Eradication of disseminated murine leukemia by treatment with high dose interleukin 2. J Immunol 137: 3675Google Scholar
  22. 22.
    Vaage J Local and systemic effects during interleukin-2 therapy of mouse mammary tumours. Cancer Res 47: 4296Google Scholar
  23. 23.
    West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898Google Scholar
  24. 24.
    Winkelhake JL, Stampfl S, Zimmerman RJ (1987) Synergistic effects of combination therapy with human recombinant interleukin 2 and tumor necrosis factor in murine tumor models. Cancer Res 47: 3948Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Riks A. Maas
    • 1
  • D. Henk
    • 1
  • J. Van Weering
    • 1
  • Hub F. J. Dullens
    • 1
  • Willem Den Otter
    • 1
  1. 1.Experimentele PathologieAcademisch Ziekenhuis UtrechtUtrechtThe Netherlands

Personalised recommendations